Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)

Next Previous
Trial Profile

A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clazosentan (Primary)
  • Indications Cerebral vasospasm
  • Focus Registrational; Therapeutic Use
  • Acronyms REACT
  • Sponsors Idorsia Pharmaceuticals

Most Recent Events

  • 01 Jan 2025 According to the results published at published in the Journal of Neurosurgery, Primary endpoint (Occurrence of Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI) From Study Drug Initiation up to 14 Days Post-study Drug Initiation) has not been met.
  • 01 Jan 2025 Results(n=409 patients, between February 2019 and May 2022 across 74 international sites) assessing the safety and efficacy of clazosentan, published in the Journal of Neurosurgery
  • 06 Feb 2023 According to an Idorsia Pharmaceuticals media release, the company will publish the data and interpretation in scientific literature in due course.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top